Clinical Trials

Thyroid eye disease is an autoimmune inflammatory disorder that can be vision-threatening and disfiguring.

New medical therapies are emerging to prevent and treat the disabling consequences of the disease.

We are involved in multiple clinical trials aimed at providing targeted therapy for TED.

What is TED?

  • Double Vision
  • Bulging Eyes
  • Redness & Swelling
  • Inability to close the eyes
  • Tearing & Irritation

Treatment costs are covered for patients who meet criteria for enrollment in Clinical Trials

You will be compensated for your time and travel

Inclusion Criteria

  • Age 18 years of age or older
  • Have clinical symptoms and signs of Thyroid Eye Disease
  • Both men and women need to avoid becoming pregnant during study screening up to and including 100 days after the last dose of study medication
  • Be willing and able to comply with all the requirements of the protocol for the entire duration of the study

Current Clinical Trials

Viridian (VRDN-001-302): NCT06179875

Viridian (VRDN-001-301): NCT05176639

Tourmaline (TOUR006-T01): NCT06088979

Immunovant (IMVT-1401-3201): NCT05517421

Horizon (HZNP-TEP-305): NCT06248619

Lassen (LASN01-CL-2201): NCT06226545

For more information on Thyroid Eye Disease click the link below:

Our Team

Kimberly Cockerham, MD, FACS
Principal Investigator, Thyroid Eye Disease Clinical Trials
Neuro-ophthalmology, Oculofacial plastic Surgery & Orbital Oncology

Rocio Gonzalez Beristain, MS, MPH
Clinical Research Coordinator
VRDN-001 Clinical Study

Emma
Front Office Coordinator
Lead for Horizon/Amgen and Tourmaline

Serena
Surgical Concierge

Helps facilitate your surgery in the office or at an ambulatory surgery center.

Karen
Certified Ophthalmic Technician
Research coordinator
Lead for Viridian and Genentech

Raul Hernandez Rubio, DO
Clinical Fellow, 2023-2024
Sub-PI for all clinical trials

Nate
Medical Assistant
Clinical research coordinator
Lead for Immunovant and Lassen